Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Spruce Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Spruce Biosciences's operating margin for the twelve months ending Sep 30, 2025 was -7100.0%. For fiscal 2024 it was -1143.4%, against -515.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -1143.4% | −628.0 |
| FY2023 | Dec 31, 2023 | -515.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -3453.9% | −3067.2 |
| Q3 FY2024 | Sep 30, 2024 | -1562.8% | −1118.3 |
| Q2 FY2024 | Jun 30, 2024 | -623.4% | +22.0 |
| Q1 FY2024 | Mar 31, 2024 | -631.0% | +41.0 |
| Q4 FY2023 | Dec 31, 2023 | -386.7% | – |
| Q3 FY2023 | Sep 30, 2023 | -444.5% | – |
| Q2 FY2023 | Jun 30, 2023 | -645.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -672.0% | – |
See a number that looks wrong?